Funding opportunity
Index Ventures has announced the closing of a €350 million early stage fund, Index Ventures V, which will be invested in early-stage and seed investments in technology, biotechnology and cleantech sectors across Europe, the United States and Israel.
This is the fifth early-stage fund Index has raised in the past ten years. The fund was raised almost entirely from the firm’s existing base of limited partners.
“Over the past twelve years, we have been fortunate enough to work with some of the most successful entrepreneurs in the world who have started game-changing companies such as Betfair, Skype, MySQL and GenMab,” said Bernard Dallé, a partner at Index. “There are certainly challenges facing many industries right now but, thanks to the ongoing commitment of our limited partners, we can continue to focus on our core strength of finding and supporting ambitious, dedicated entrepreneurs.”
Investments made during the last twelve months include: Criteo, in France, DimDim India, Lehigh Technologies, US, MyHeritage, Israel, NormOxys, France, OpTier, Israel, Playfish, UK, RightScale, US, and WooMe, UK/US.
Francesco De Rubertis, a partner at Index, said, “On the biotech side, Index is focused on finding the best companies with the strongest pipelines. We are equally interested in very early-stage ventures and more mature companies with established proof-of-concept. In terms of therapeutic areas, our priorities are oncology, central nervous system diseases, immunology and inflammation.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
